Nagendran Sukumar, president and head of R&D at Taysha Gene Therapies, sold 200,000 shares for $1.2 million on July 10, 2026, after the stock surged 149% over the prior year. The sale, executed under a Rule 10b5-1 trading plan adopted in June 2025, reduced his direct holdings by 18% to 936,410 shares, a stake worth $5.94 million based on a recent close of $6.34. Taysha, a clinical-stage biotech focused on gene therapies for central nervous system diseases, has a market cap of $1.60 billion and reported a trailing net loss of $129.9 million on $7.5 million in revenue. The company recently reaffirmed FDA alignment on a BLA pathway for its Rett syndrome gene therapy TSHA-102, with the pivotal REVEAL trial completing dosing of 17 patients and showing durable treatment across all age groups.
Taysha Gene Therapies IncInsider stock sale by R&D chief, but executed under a pre-arranged 10b5-1 plan, reducing holdings by 18% after a 149% run-up.